GCP
BLTE

GSA Capital Partners’s Belite Bio BLTE Stock Holding History

GSA Capital Partners’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$672K Buy
4,364
+2,719
+165% +$417K 0.04% 794
2026
Q1 		$262K Buy
1,645
+182
+12% +$30.6K 0.02% 1323
2025
Q4 		$234K Buy
+1,463
New +$173K 0.02% 1316

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GSA Capital Partners's BLTE Position: Q2 2026 in Review

GSA Capital Partners increased its Belite Bio (BLTE) stake by 165% in Q2 2026, buying an estimated $417K and bringing the position to 4,364 shares worth $672K. The position accounts for 0.04% of the portfolio, ranked #794.

GSA Capital Partners first reported a position in BLTE in Q4 2025 and has held it in 3 quarters since. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • GSA Capital Partners held 4,364 shares of Belite Bio worth $672K as of Q2 2026.
  • GSA Capital Partners bought 2,719 Belite Bio shares in Q2 2026, an estimated $417K.
  • Belite Bio made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #794 holding.
  • GSA Capital Partners first reported a position in Belite Bio in Q4 2025 and has held it in 3 quarters since.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.